Disparities in Cancer Screening: Lower Income Linked to Reduced Participation in France

A recent study by the Department of Research, Studies, Evaluation and Statistics (DREES) reveals a significant disparity in cancer screening rates in France, with individuals from lower socioeconomic backgrounds less likely to participate in screenings for breast, colorectal, and cervical cancers compared to their wealthier counterparts.

Screening Rates and Socioeconomic Status

Despite national screening programs and full coverage of costs, participation rates vary considerably based on income level. The DREES analysis, covering the period 2017-2020, highlights these inequalities.

• Colorectal Cancer: Screening participation among those aged 50-74 is twice as frequent for the wealthiest 10% (31%) compared to the poorest 10% (16%). [DREES]
• Breast Cancer: Participation in both organized and individual breast cancer screening increases with standard of living, ranging from 42% for the poorest 10% to 67% for the wealthiest 10%. [DREES]
• Cervical Cancer: Individuals with higher incomes are 1.6 times more likely to utilize organized cervical cancer screening than those with lower incomes.

The study also indicates that wealthier individuals receive more mammograms and ultrasounds before the age of 50, and are 1.8 times more likely to complete HPV vaccination at age 16.

Factors Contributing to Disparities

The DREES identifies both financial barriers and factors related to information access and healthcare relationships as contributing to these disparities. These include:

• Financial Barriers: Direct or anticipated costs associated with screening and follow-up care, even when partially covered.
• Information Access: Less familiarity with screening recommendations.
• Healthcare Relationships: Social distance from healthcare professionals and unfavorable perceptions of examinations or prognosis.

These obstacles can be amplified for individuals with disabilities or mental health disorders.

Recommendations for Improvement

To address these inequalities, DREES recommends implementing additional actions to reach populations least inclined to participate in preventative care. [DREES]

Recent Advances in French Cancer Care

France is actively innovating in cancer care, with a focus on targeted therapies, precision medicine, and the use of artificial intelligence (AI). [French Healthcare]

• Targeted Therapies: Antibody-drug conjugates (ADCs) like trastuzumab deruxtecan are demonstrating superior efficacy in early breast cancer treatment.
• Precision Medicine: Molecular profiling and biomarkers are being used to tailor treatment to individual patients.
• AI and Data: Collaborations between institutions like Curie and Google are developing AI models to improve diagnosis and predict treatment responses.

The French Early Breast Cancer Cohort (FRESH) is a unique resource for breast cancer research, including all French women aged 18 or over treated for early-stage breast cancer. [PMC]